Abionyx Pharma announces that the Phase 2a pilot clinical trial evaluating CER-001 as a treatment for septic patients at high risk of developing acute renal failure (ARF) has met both primary and secondary endpoints.

The biopharmaceutical company reports a direct and significant effect of CER-001 on the elimination of endotoxins and a consequent reduction in the inflammatory cascade or "cytokine storm" at the end of this RACERS study, which involved 20 patients.

There was also a significant protective effect on endothelial function, and a trend towards a reduction in the number of ICU days for treated patients and in the need for organ replacement, as well as an improvement in 30-day survival.

The safety and efficacy observed in RACERS were generally in line with historical data. These data will be discussed with regulatory authorities, starting in Europe and the United States later this year.

Copyright (c) 2023 CercleFinance.com. All rights reserved.